ALEXION PHARMACEUTICALS INC - COM (ALXN)

Historical Institutional Holders from Q1 2014 to Q4 2024

All holders as of December 31, 2024
Q4 2024
Type / Class
Equity / COM
Shares, excl. options Q4 2024
6.94K
Holdings value Q4 2024
$924K
Value change Q4 2024
$0
Grand Portfolio weight change Q4 2024
0%
Number of holders
1
Number of buys Q4 2024
0
Number of sells Q4 2024
0
Average buys Q4 2024 %
0
Average sells Q4 2024 %
0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q4 6.94K $924K $0 $133.06 1
2024 Q1 0 $0 -$8.83K 0
2023 Q4 61 $8.83K $0 $144.70 1
2023 Q3 61 $10.4K $0 $169.89 1
2023 Q2 61 $13.6K $0 $222.49 1
2023 Q1 61 $13K $0 $213.11 1
2022 Q4 61 $13K $0 $213.11 1
2022 Q3 61 $16K +$262 $262.30 1
2022 Q2 60 $13K $0 $216.67 1
2022 Q1 60 $13K $0 $216.67 1
2021 Q4 60 $14K -$596K $233.33 1
2021 Q3 3.21K $555K -$46.7B $200.21 6
2021 Q2 209M $38.4B +$1.64B $183.71 686
2021 Q1 203M $31B +$1.1B $152.91 732
2020 Q4 199M $31B +$122M $156.24 794
2020 Q3 199M $22.7B -$207M $114.43 688
2020 Q2 199M $22.3B +$60.1M $112.24 685
2020 Q1 199M $17.9B -$258M $89.79 629
2019 Q4 202M $21.9B -$287M $108.15 645
2019 Q3 205M $20.1B -$751M $97.94 626
2019 Q2 210M $27.5B +$365M $130.98 627
2019 Q1 214M $28.9B +$634M $135.18 602
2018 Q4 211M $20.5B -$103M $97.36 592
2018 Q3 212M $29.4B +$284M $139.01 582
2018 Q2 210M $26.1B +$296M $124.15 594
2018 Q1 209M $23.3B -$281M $111.46 589
2017 Q4 211M $25.3B -$477M $119.59 581
2017 Q3 214M $30B +$78.9M $140.29 590
2017 Q2 214M $26B +$132M $121.67 552
2017 Q1 214M $25.9B +$1.4B $121.24 556
2016 Q4 220M $26.9B +$339M $122.35 546
2016 Q3 217M $26.6B -$80.8M $122.54 510
2016 Q2 217M $25.4B -$138M $116.76 524
2016 Q1 219M $30.4B -$548M $139.22 509
2015 Q4 223M $42.5B -$151M $190.75 542
2015 Q3 224M $35B +$824M $156.39 507
2015 Q2 219M $39.7B +$4.79B $180.77 537
2015 Q1 193M $33.4B +$79.3M $173.30 558
2014 Q4 192M $35.6B +$60.6M $185.03 570
2014 Q3 191M $31.7B +$272M $165.82 513
2014 Q2 190M $29.7B -$127M $156.25 516
2014 Q1 191M $29B +$107M $152.13 499